Table II.
Formulation | Method | Particle Size (nm) |
Encapsulation Efficiency (%) |
Advantages | Disadvantages | Refs. |
---|---|---|---|---|---|---|
PLGA NPs of curcumin for oral administration. | Solvent Evapration Diffusion | 120–240 (PDI = 0.31) | 77 |
|
37 | |
PLGA and PEG NPs of curcumin for parenteral administration. | Nano-precipitation | 80–90 | 97.5 |
|
35 | |
NIPAAM NPs of curcumin containing PEG monoacrylate. | Micellar Aggregation | ~50 | >90 |
|
36 | |
PLGA NPs of curcumin coated with thiolated chitosan. | Emulsion Solvent Evaporation | 578±67 (pH 7.4) | 28 |
|
|
51 |
Butylcyanoacrylate NPs of curcumin coated with poloxamer 188. | Anionic Polymerization Solvent Evaporation | 160–240 (PDI ~0.25) | 78 |
|
59 | |
NIPAAM NPs of curcumin multi layered with PLGA. | Free Radical Polymeriz -ation Double Emulsion Solvent Evaporation | 500–1000 | 49.5 |
|
|
65 |
Surface modified DMPC SLNs for parenteral administration. | Extrusion through 0.2 µM filter | 187±53 | 97 |
|
|
74 |